Arni Blöndal
Managing Partner @ Brunnur Ventures
Reykjavík, Iceland
Arni Blöndal is a seed investor at Brunnur Ventures in Reykjavík focused on Biotechnology and B2C. Arni Blöndal - Managing Partner @ Brunnur Ventures
- Total investments:
- 7
- Last investment:
- Lead investor:
- 57%
Last updated:
For AI agents: llms.txt
Industries Arni Blöndal invests in
Stages Arni Blöndal invests in
Countries Arni Blöndal invests in
Investment Focus
Industry
- Biotechnology 2 (29%)
- B2C 1 (14%)
- Rental 1 (14%)
- Travel 1 (14%)
- Medical 1 (14%)
Stage
- Seed 2 (29%)
- Pre-Seed 1 (14%)
- Series A 1 (14%)
- Series B 1 (14%)
- Series C 1 (14%)
Country
- Iceland 2 (29%)
- Japan 1 (14%)
- United States 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Axelyf
|
Axelyf is a biotechnology company that offers RNA medicines through safer and more effective lipid nanoparticle delivery. | $7.4M / Seed / Aug 07, 2025 | |
Trip To Japan
|
Trip to Japan is a travel booking platform that focuses on creating customizable itineraries for travelers. The platform offers a variety of options, including hotels, ryokans, JR Passes, cultural tours, sightseeing, and adventure trips. With a selection of pre-planned and tailored travel packages, Trip to Japan provides easy online booking andfree cancellations. | $150K / Pre-Seed / Jul 01, 2023 | |
Standby Deposits
|
Standby Deposits is a developer of a renting deposit alternative platform for renters. Its platform connects landlords and tenants and eliminates security deposits by allowing renters to rent property based on their rental credit score along with banking integration to transfer rents on time. | $5.3M / Seed / Apr 19, 2023 | |
Oculis
|
The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $57M / Series C / May 04, 2021 | |
|
Oculis
|
The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $18.1M / Series B / Jan 04, 2019 | |
|
Oculis
|
The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $23.3M / Series B / Jan 04, 2018 | |
|
Oculis
|
The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | Series A / Aug 16, 2016 |
Co-Investors
About Brunnur Ventures
Brunnur Ventures invests in entities in Iceland and has the ability to invest abroad as a part of the expansion of its portfolio companies internationally. The venture firm does not have a specific industry focus. However, it investments in companies that show great growth potential in specific industry sectors. Brunnur Ventures is the GeneralPartner of Brunnur Venture Capital Fund a USD 40M fund.
Brunnur Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Arni Blöndal
Managing Partner
|
|||
Sigurdur Arnljotsson
Founding Partner
|
|||
Kjartan Olafsson
Venture Partner
|
|||
Margret Ormslev Asgeirsdottir
Partner
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Arni Blöndal invest in?
Arni Blöndal invests primarily in Biotechnology, B2C and Rental startups, most often at Seed and Pre-Seed stage. Most of the 7 investments tracked by Shizune back companies in Iceland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Arni Blöndal last invest?
The most recent investment recorded for Arni Blöndal closed in Aug 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
